TY - JOUR
T1 - Subjective and cardiovascular effects of cocaine during treatment with amantadine and baclofen in combination
AU - Rotheram-Fuller, Erin
AU - De La Garza, Richard
AU - Mahoney, James J.
AU - Shoptaw, Steve
AU - Newton, Thomas F.
N1 - Funding Information:
The authors would like to acknowledge NIDA grant no. 1 DA P50 18185 for this project.
PY - 2007/8/30
Y1 - 2007/8/30
N2 - This study assessed the subjective and cardiovascular effects of relevant doses of cocaine administration during steady-state treatment of the combination of amantadine and baclofen compared to placebo. Participants included 8 healthy, male, cocaine-dependent, non-treatment-seeking individuals (age = 36.6 ± 5.9; 75% African American, 25% Caucasian; using cocaine for an average of 15.3 ± 6.5 years). Data were collected prior to and following double-blind intravenous administration of 0 mg, 20 mg, and 40 mg of cocaine. Data were collected at baseline, following 5 days of treatment with placebo, and again following 5 days of treatment with a combination of amantadine 100 mg t.i.d. and baclofen 30 mg t.i.d. counterbalanced for order of medication and placebo in a cross-over design. Results showed no significant alterations to cardiovascular variables (heart rate, systolic and diastolic blood pressure) from treatment using combination medication or placebo in the presence of cocaine. Self-rated "desire" for cocaine was significantly lower during cocaine administrations while participants were receiving treatment with amantadine-baclofen compared to infusions while taking placebo medication, although there was no difference in the intensity of cocaine-induced euphoria, or reduction in the likelihood to use cocaine if given access. Study findings support the safety of the amantadine-baclofen combination treatment for cocaine dependence.
AB - This study assessed the subjective and cardiovascular effects of relevant doses of cocaine administration during steady-state treatment of the combination of amantadine and baclofen compared to placebo. Participants included 8 healthy, male, cocaine-dependent, non-treatment-seeking individuals (age = 36.6 ± 5.9; 75% African American, 25% Caucasian; using cocaine for an average of 15.3 ± 6.5 years). Data were collected prior to and following double-blind intravenous administration of 0 mg, 20 mg, and 40 mg of cocaine. Data were collected at baseline, following 5 days of treatment with placebo, and again following 5 days of treatment with a combination of amantadine 100 mg t.i.d. and baclofen 30 mg t.i.d. counterbalanced for order of medication and placebo in a cross-over design. Results showed no significant alterations to cardiovascular variables (heart rate, systolic and diastolic blood pressure) from treatment using combination medication or placebo in the presence of cocaine. Self-rated "desire" for cocaine was significantly lower during cocaine administrations while participants were receiving treatment with amantadine-baclofen compared to infusions while taking placebo medication, although there was no difference in the intensity of cocaine-induced euphoria, or reduction in the likelihood to use cocaine if given access. Study findings support the safety of the amantadine-baclofen combination treatment for cocaine dependence.
KW - Amantadine
KW - Baclofen
KW - Cocaine
KW - Pharmacotherapy
KW - Phase I Clinical Trial
UR - http://www.scopus.com/inward/record.url?scp=34547684290&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34547684290&partnerID=8YFLogxK
U2 - 10.1016/j.psychres.2006.03.012
DO - 10.1016/j.psychres.2006.03.012
M3 - Article
C2 - 17449110
AN - SCOPUS:34547684290
SN - 0165-1781
VL - 152
SP - 205
EP - 210
JO - Psychiatry Research
JF - Psychiatry Research
IS - 2-3
ER -